Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2009-03-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Three Arm Trial of Immune Effects of Echinacea
NCT01129128
Effects of Echinacea in Children
NCT00773435
Evaluation of Echinacea for the Common Cold
NCT00032500
Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections
NCT03812900
Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)
NCT00065715
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Echinacea
Echinacea purpurea
Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
placebo
placebo
placebo 25 ml daily in 2 divided doses for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echinacea purpurea
Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
placebo
placebo 25 ml daily in 2 divided doses for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If female of child-bearing potential, willing to use contraception to prevent pregnancy
* Speaks and reads English
* No use of any medication (other than multivitamins, essential fatty acids or probiotics)
* Willing to abstain from ingesting edible mushrooms throughout study
* Willing to eat less than 2 garlic cloves per day throughout study
Exclusion Criteria
* History of autoimmune disease
* History of allergic rhinitis
* History of physician diagnosed eczema
* Known allergic reaction to Echinacea or related species, specifically ragweed (Ambrosia), chamomile (Matricaria), goldenrod (Solidago) and sunflower (Helianthus)
* Use of any medication within 30 days prior to first dose of study medication that is a known inhibitor or inducer of CYP34A
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Complementary and Integrative Health (NCCIH)
NIH
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James Taylor
School of Medicine: Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James A Taylor, MD
Role: PRINCIPAL_INVESTIGATOR
University of Washington
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bastyr University
Kenmore, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09A1236
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.